Antisense raf oligodeoxyribonucleotide is a radiosensitizer in vivo

Antisense and Nucleic Acid Drug Development

Volumn 9, Issue 2, 1999, Pages 191-201

  Gokhale, Prafulla C ^a   McRae, Donald ^a   Monia, Brett P ^c   Bagg, Adam ^b   Rahman, Aquilur ^a,d   Dritschilo, Anatoly ^a   Kasid, Usha ^a,e  

^a GEORGETOWN UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^c ISIS PHARMACEUTICALS   (United States)

^d NeoPharm Inc   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; LIPOSOME; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; RADIOSENSITIZING AGENT; RAF PROTEIN;

ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CANCER REGRESSION; CHROMATIN; CONTROLLED STUDY; ENCAPSULATION; HALF LIFE TIME; HEART; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IONIZING RADIATION; KIDNEY; LARYNX CARCINOMA; LIVER LEVEL; LUNG; PRIORITY JOURNAL; RADIOSENSITIZATION; SPLEEN; SQUAMOUS CELL CARCINOMA;

EID: 0033031520     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1999.9.191     Document Type: Article

References (9)

1. AGRAWAL, S., ZHAO, Q., JIANG, Z., OLIVER, C., GILES, H., HEATH, J., and SEROTA, D. (1997). Toxicologic effects of an oligodeoxynucleotide phosphorothioate and its analogs following intravenous administration in rats. Antisense Nucleic Acid Drug Dev. 7, 575-584.
2. AKHTAR, S., and AGRAWAL, S. (1997). In vivo studies with antisense oligonucleotides. Trends Pharmacol. Sci. 18, 12-18.
3. BAYEVER, E., IVERSON, P.L., BISHOP, M.R., SHARP, G.J., TEWARY, H.K., ARNESON, M.A., PIRRUCCELLO, S.J., RUDDON, R.W., KESSINGER, A., ZON, G., and ARMITAGE, J.O. (1993). Systemic administration of a phosphorothioate oligonucleotide with a sequence complementary to p53 for acute myelogenous leukemia and myelodyeplastic syndrome: Initial results of a phase I trial. Antisense Res. Dev. 3, 383-390.
4. BISHOP, M.R., IVERSON, P.L., BAYEVER, E., SHARP, G.J., GREINER, T.C., COPPLE, B.L., RUDDON, R.W., ZON, G., SPINOLO, J., ARNESON, M., ARMITAGE, J.O., and KESSINGER, A. (1996). Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies. J. Clin. Oncol. 14, 1320-1326.
5. BROCKSTEIN, B., HARAF, D.J., STENSON, K., FASANMADE, A., STUPP, R., GLISSON, B., LIPPMAN, S.M., RATAIN, M.J., SULZEN, L., KLEPSCH, A., WEICHSELBAUM, R.R., and YOKES, E.E. (1998). Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck. J. Clin. Oncol. 16, 735-744.
6. CROOKE, S.T. (1998). An overview of progress in antisense therapeutics. Antisense Nucleic Acid Drug Dev. 8, 115-122.
7. 14C-labeled afovirsen sodium in patients with genital warts. Clin. Pharmacol. Ther. 56, 641-646.
8. DEVARY, Y., GOTTLIEB, R.A., SMEAL, T., and KARIN, M. (1992). The mammalian ultraviolet response is triggered by activation of Src tyrosine kinases. Cell 71, 1081-1091.
9. ZHAO, Q., MATSON, S., HERRARA, C.J., FISHER, E., YU, H., WAGGONER, A., and KRIEG, A.M. (1993). Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. Antisense Res. Dev. 3, 53-66.